Skip to main content
Lini Pandite on Muck Rack

Lini Pandite

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lini

Contact Lini, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

|
By Yvette Drew, Lucy Gilbert, Alejandro Bueno, Ana Oaknin, Victor Moreno, Lydia Garcia, Gordon C Jayson, Rebecca S Kristeleit, Nehal Lakhani, Susana Banerjee, Daniela Matei, Amit M Oza, Rowan Miller, Dennis Yiannakis, Jerónimo García, Guanfang Wang, Debra Richardson, Maria-Pilar Barretina-Ginesta, Jayalakshmi Miriyala, Amy Franke, Elisa Galvez, Lini Pandite
| Nature Verified
Abstract Platinum resistant ovarian cancer (PROC) is associated with poor survival. This clinical trial sought to determine whether the bispecific CD47 inhibitor and CD40 agonist, SL-172154, could be combined safely and improve the efficacy of mirvetuximab (MIRV) or pegylated liposomal doxorubicin (PLD) through enhanced tumor cell phagocytosis and antigen presentation to T cells.
Open in Who Shared Issue with article?
See all 1 articles